US20070026070A1 - Cross-linked polysaccharide composition - Google Patents

Cross-linked polysaccharide composition Download PDF

Info

Publication number
US20070026070A1
US20070026070A1 US10/552,881 US55288106A US2007026070A1 US 20070026070 A1 US20070026070 A1 US 20070026070A1 US 55288106 A US55288106 A US 55288106A US 2007026070 A1 US2007026070 A1 US 2007026070A1
Authority
US
United States
Prior art keywords
gel
cross
polysaccharide
process according
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/552,881
Other languages
English (en)
Inventor
Simone Vonwiller
Geoffrey Heber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultraceuticals R&D Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to ULTRACEUTICALS R & D PTY. LIMITED reassignment ULTRACEUTICALS R & D PTY. LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEBER, GEOFFREY KENNETH, VONWILLER, SIMONE CHARLOTTE
Publication of US20070026070A1 publication Critical patent/US20070026070A1/en
Priority to US14/141,018 priority Critical patent/US8877243B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Definitions

  • the present invention relates to cross-linked polysaccharide compositions, processes for preparing the compositions, and uses of the compositions in cosmetic, medical and pharmaceutical applications.
  • Hyaluronic acid is a member of a class of polymers known as glycosaminoglycans.
  • HA is a long chain linear polysaccharide and is usually present as a sodium salt having the molecular formula (C 14 H 20 NNa 11 ) n where n may vary according to the source of the HA and the method of isolating the HA.
  • Molecular weights of HA of up to 14 ⁇ 10 6 have been reported.
  • HA and its salts may be isolated from many sources including the human umbilical cord, rooster combs and nearly all connective matrices of vertebrate organisms.
  • HA is also a capsular component of bacteria such as streptococci and may therefore be obtained by fermentation methods such as reported in U.S. Pat. No. 5,411,874 (Fermentech Ltd).
  • HA is non-immunogenic and therefore has great potential in medicine. Because of its visco-elastic properties, HA having a high molecular weight (over 1 million) has been found to be particularly useful in a variety of clinical fields, including wound treatment, ophthalmic surgery, orthopedic surgery and drug delivery. HA is also potentially useful in a variety of non-medical fields, including cosmetic applications.
  • HA is degraded by enzymes such as hyaluronidase and free radicals found in the human body. Furthermore, HA is soluble in water at room temperature, which may also make it less suited to certain applications.
  • HA has been cross-linked via an ether linkage and carboxyl groups via an ester linkage.
  • HA has been cross-linked at pH levels less than 9 at which ester bonds form via carboxyl groups, and at pH levels greater than 9 at which ether bonds form via hydroxyl groups.
  • the present inventors have found that ether bonds may be beneficial because these bonds are more resistant to physiological degradation.
  • U.S. Pat. No. 5,827,937 reports polysaccharide gel compositions prepared by forming an aqueous solution of the polysaccharide, initiating cross-linking in the presence of a polyfunctional cross-linking agent, sterically hindering the cross-linking reaction from being terminated before gelation occurs (e.g. by diluting the solution) and then reintroducing sterically unhindered conditions (e.g. by evaporating the solution) so as to continue the cross-linking such that a viscoelastic gel is formed.
  • the cross-linking in this method may be performed under alkaline or acidic conditions.
  • WO 00/46253 reports cross-linking HA with other polymers by two different types of cross-linking bonds.
  • the formation of different types of bonds is achieved by cross-linking via different functional groups.
  • one type of bond may be formed by cross-linking via hydroxyl groups, and a different functional bond may be formed by cross-linking via carboxyl groups.
  • WO 87/07898 reports reacting a polysaccharide with a polyfunctional epoxide, removing excess epoxide and employing a drying operation to cross-link the polysaccharide into a film, powdered material or similar dry product.
  • U.S. Pat. No. 4,963,666 reports a process in which a polysaccharide is monosubstituted with a cross-linking agent at low concentration under alkaline conditions to form ether linkages.
  • the mixture is washed to pH 5.5 inducing some ester linkages and then, in one example, concentrated by slow evaporation to complete cross-linking with ester linkages.
  • the pH is increased by the addition of ammonia, and then slowly evaporated to complete the cross-linking with primarily ether linkages and some ester linkages.
  • the present invention provides a process for producing a cross-linked polysaccharide gel.
  • a polysaccharide mixed with an alkaline medium is contacted with a bifunctional or polyfunctional epoxide to form an essentially epoxy cross-linked polysaccharide in which the epoxide is linked to the polysaccharide substantially by ether bonds.
  • the epoxy cross-linked polysaccharide is then dried without removing the epoxide from the alkaline medium.
  • the resulting dried cross-linked polysaccharide matrix may then be washed in a suitable water miscible solvent, and treated with an acidic medium to form a cross-linked polysaccharide gel.
  • polysaccharide starting materials may be used in embodiments of the present invention.
  • Suitable polysaccharides include HA, pectin, xanthan or alginic acid, as well as anionic derivatives of carboxymethyl cellulose, carboxymethyl dextran or carboxymethyl starch.
  • HA may be a particularly suitable starting material.
  • Suitable epoxides for use as the cross-linking agent include 1,4-butanediol ether, 1,2-ethanediol diglycidyl ether and/or epoxy-substituted pentaerythritol. It will be appreciated, however, that other epoxides may also be suitable for the present invention.
  • the present invention provides a cross-linked polysaccharide gel prepared by the process reported herein.
  • the gel may have improved degradation characteristics when administered to a patient.
  • the present invention provides a biocompatible gel including HA cross-linked substantially by ether bonds with 1,4-butanediolglycidyl ether that is sufficiently cross-linked to resist to degradation.
  • the phrase “sufficiently cross-linked to resist degradation” means that the gel is relatively stable to hyaluronidase attack under physiological conditions over prolonged periods or can tolerate extrusion or being expelled from a small gauge needle.
  • the present inventors have been able to produce biocompatible gels which release less than 75 percent uronic acid when 0.4 ml of the gel having a concentration of 15 mg/ml is combined with 0.5 mg hyaluronidase and 3 ml phosphate buffered saline, and stored at a temperature of at least 37° C. for two days. Uronic acid release may be measured by the UV absorbance techniques reported in the Examples.
  • the gels may release no more that 70 percent uronic acid, more particularly no more that 65 percent uronic acid under the foregoing conditions.
  • the present invention provides a process for producing a cross-linked polysaccharide gel comprising:
  • the present invention provides a cross-linked polysaccharide gel substantially resistant to hyaluronidase degradation prepared by the process according to the first aspect of the present invention.
  • the present invention provides a biocompatible gel comprising hyaluronic acid cross-linked substantially by ether bonds with 1,4-butanediol diglycidyl ether such that the gel is sufficiently cross-linked to substantially resist degradation.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a cross-linked polysaccharide gel according to the second aspect of the present invention; a biologically active substance; and a pharmaceutically acceptable carrier.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a biocompatible gel according to the third aspect of the present invention; a biologically active substance; and a pharmaceutically acceptable carrier.
  • the present invention provides a method of treating or preventing a disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a gel according to the fourth aspect of the present invention.
  • the present invention provides a method of treating or preventing a disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition according to the fifth aspect of the present invention.
  • the present invention provides use of a gel according to the third aspect of the present invention in the manufacture of a medicament for treating or preventing a disorder in a subject in need thereof.
  • the present invention provides use of a pharmaceutical composition according to the fourth aspect of the present invention in the manufacture of a medicament for treating or preventing a disorder in a subject in need thereof.
  • FIG. 1 shows the titration curve of hyaluronidase on a hyaluronic acid substrate. as reported in the Examples.
  • FIG. 2 shows a comparison of uronic acid (UA) release between samples A and B as reported in the Examples.
  • FIG. 3 shows the UV absorption of UA in gels after 1 day as reported in the Examples.
  • FIG. 4 shows the UV absorption of UA at 530 nm at one, two and twelve days as reported in the Examples.
  • FIG. 5 shows the UV absorption of UA at 530 nm, after two days incubation as reported in the Examples.
  • FIG. 6 shows a comparison between various gels as reported in the Examples.
  • the present invention provides a process for making a polysaccharide cross-linked gel.
  • the process generally includes the steps of:
  • the gel has improved resistance to degradation when compared to conventional cross-linked polysaccharide gels.
  • the polysaccharide starting material may be selected from a wide range of suitable naturally-occurring carboxylate-containing polysaccharides, including HA, pectin, xanthan, or alginic acid, as well as anionic derivatives of neutral polysaccharides such as carboxymethyl cellulose, carboxymethyl dextran or carboxymethyl starch.
  • HA is used as the polysaccharide starting material.
  • HA may be extracted from a number of sources, for example, cocks' combs.
  • a suitable purified HA fraction is the “noninflammatory-NIF-NaHA sodium hyaluronate”, reported by Balazs in the pamphlet “Healon”—A guide to its use in Ophthalmic Surgery—D. Miller & R. Stegmann, eds. John Wiley & Sons N.Y. 81983: p. 5.
  • Suitable HA starting materials include “Hyalastine” brand and “Hyalectin” brand HA.
  • the fraction Hyalastine has an average molecular weight of about 50,000 to 100,000 while the fraction Hyalectin has an average molecular weight of about 500,000 to 730,000.
  • a combined fraction of these two fractions has also been isolated and characterized as having an average molecular weight of between about 250,000 and about 350,000. This combined fraction may be obtained with a yield of 80% of the total hyaluronic acid available in the particular starting material, while the fraction Hyalectin may be obtained with a yield of 30% and the fraction Hyalastine with a yield of 50% of the starting HA.
  • the preparation of these fractions is reported in European patent publication No. 0138572A3.
  • Other suitable HA starting materials include the fibrous and powdered HA materials reported in the Examples below.
  • the polysaccharide may be cross-linked by a variety of suitable polyfunctional cross-linking epoxides, including bi- or polyfunctional epoxides, such as lower aliphatic epoxides or their corresponding epihalohydrins.
  • suitable polyfunctional cross-linking epoxides include 1,4-butanediol diglycidyl ether (BDDE), 1,2-ethanediol diglycidyl ether, epoxy-substituted pentaerythritol (e.g. SHELL 162) and epihalohydrins thereof.
  • the poly-functional cross-linking agent includes 1,4-butanediol diglycidyl ether.
  • the polysaccharide starting material may be combined with the cross-linking agent in an alkaline medium.
  • polysaccharide may be added to the alkaline medium.
  • the alkaline medium may be formed with sodium hydroxide or other suitable basic materials.
  • the concentration of sodium hydroxide or other basic material may be between about 0.1 and about 1 w/v percent, more particularly about 1% of the total mixture.
  • the cross-linking agent may be added to the alkaline mixture to produce a cross-linking agent concentration between about 0.05 and about 0.5%, more particularly about 0.1%.
  • the alkaline medium may have a pH between about 9 and 12, more particularly, about 9.
  • the resulting alkaline mixture may be incubated under conditions that promote cross-linking of the polysaccharide with the epoxide.
  • the mixture may be incubated in a water bath at about 45° C. for about 2 hours.
  • HA cross-linked under these conditions will substantially include ether bonds which are generally more resistant to physiological degradation than ester bonds formed under acidic conditions.
  • the cross-linked mixture may be dried by conventional methods to form a polysaccharide matrix.
  • the cross-linked mixture may be dried by stirring the mixture vigorously and removing the water under high vacuum for about 1.5 hours at between about 35° C. and 45° C.
  • the polysaccharide matrix may be washed with a water miscible solvent, for example an isopropyl alcohol/water co-solvent, for several hours.
  • the washed matrix may be neutralised with an acidic medium to form a cross-linked polysaccharide gel.
  • the matrix may be treated with a solution of 1-2 percent acetic acid in water to form the cross-linked polysaccharide gel.
  • the cross-linked polysaccharide gel may be further treated with a phosphate buffered saline mixture to affect the viscosity of the gel.
  • the polysaccharide gel formed by the foregoing method is sufficiently cross-linked to resist degradation when administered to a patient. Because of the improved degradation characteristics of the gel, the resulting cross-linked polysaccharide gel may be used for a variety of applications.
  • the cross-linked polysaccharide gel may be used for augmenting tissue, treating arthritis, treating tissue adhesions, and for use in coating mammalian cells to reduce immunogenicity.
  • the cross-linked polysaccharide gel may be used in cosmetic applications, corrective implants, hormone replacement therapy, hormone treatment, contraception, joint lubrication, and ocular surgery.
  • the cross-linked polysaccharide gel remains substantially resistant to degradation following extrusion through a narrow gauge needle. Extrusion through a needle may break gels into smaller particles if the gels are not resistant to shear stress.
  • the cross-linked polysaccharide gels of embodiments of the present invention are resistant to degradation following extrusion through a small gauge needle such as a 27, 30 or 32 gauge needle.
  • these gels are particularly suitable for injection into tissue or skin without substantial loss of the structural integrity of the solution or gel.
  • the cross-linked polysaccharide gel may be combined with a biologically active substance for administration to a patient.
  • Suitable biologically active substances for use with the present invention include hormones, cytokines, vaccines, cells, tissue augmenting substances, or mixtures thereof.
  • suitable tissue augmenting substances include collagen, starch, dextranomer, polylactide, poly-beta-hydroxybutyrate, and/or copolymers thereof.
  • Suitable biologically active substances may include various alkaloids, peptides, phenothiazines, benzodiazepines, thioxanthenes, hormones, vitamins, anticonvulsants, antipsychotics, antiemetics, anesthetics, hypnotics, anorexigenics, tranquilizers, muscle relaxants, coronary vasodilators, antineoplastics, antibiotics, antibacterials, antivirals, antimalarials, carbonic anhydrase inhibitors, nonsteroid antiinflammatory agents, vasoconstrictors, cholinergic agonists, cholinergic antagonists, adrenergic agonists, adrenergic antagonists, narcotic antagonists.
  • the biologically active substance may be combined with suitable cross-linked polysaccharide gels of the present invention by physical mixing of the biologically active substance with the polysaccharide starting material.
  • the biologically active substance may be combined in solid form, for example as a freeze-dried powder or solutions.
  • cross-linked polysaccharide gel as a vehicle for biologically active substances may be particularly useful in ophthalmology, where particular compatibility between the cross-linked polysaccharide gels and the corneal epithelium exists.
  • biologically active substances are administered in the form of concentrated solutions with elastic-viscous characteristics or in solid form on the corneal epithelium, homogenous and stable films are formed that are transparent and adhering, and that provide prolonged bioavailability of the biologically active substance.
  • the cross-linked polysaccharide gel vehicles of embodiments of the present invention may also be suitable for treatment of diseases of the mucosa (e.g. diseases of the mount) and dermatological treatments.
  • the foregoing biologically active gels may be formed into pharmaceutical preparations for oral, rectal, parenteral, subcutaneous, local or intradermal use.
  • suitable pharmaceutical preparations may be in solid or semisolid form, for example pills, tablets, gelatinous capsules, capsules, suppositories or soft gelatin capsules.
  • pharmaceutical preparations intended or intramuscular or intradermal uses or infusions or intravenous injections may be used, and may therefore be presented as solutions of the active compounds or as freeze-dried powders of the active compounds to be mixed with one or more pharmaceutically acceptable excipients or diluents.
  • pharmaceutical preparations in the form of topical preparations may be suitable, for example nasal sprays, creams and ointments for topical use or sticking plasters specially prepared for intradermal administration.
  • the preparations may be administered to humans or animals.
  • the cross-linked polysaccharide gel may contain between about 0.01% and 10% of biologically active substance for solutions, sprays, ointments and creams, and between about 15% and 50% of biologically active substance for the solid form preparations.
  • alkaline medium includes, but is not limited to a hydroxide salt dissolved in water, preferably sodium hydroxide.
  • the term “acidic medium” includes, but is not limited to an organic or inorganic acid dissolved in water, preferably acetic acid.
  • the resulting transparent polysaccharide matrices were washed with an isopropyl alcohol and water mixture (IPA/H 2 O) (6:4, 25 ml) for 22 hours, and then the IPA/H 2 O mixture was replaced two more times every 22 hours (i.e. for a total wash time of 66 hours).
  • the IPA/H 2 O mixture was removed, and then 1.3 percent acetic acid in water (25 ml) was added with stirring. After 35 minutes, both samples had produced fully swollen gels with the “fibrous” gel (“Sample A”) being noticeably more viscous than the “powdered” gel (“Sample B”).
  • the gels were then subjected to a series of washes with IPA (50 ml), IPA/H 2 O (6:4, 25 ml), IPA/H 2 O (8:2, 100 ml), and then IPA (50 ).
  • the resulting opaque rubbery materials were then freeze dried to give opaque hard sheets.
  • the sheets were then reconstituted in freshly prepared phosphate buffered saline over 24 hours at concentrations of 15 and 20 mg/ml for use in the following Examples.
  • Sample A was pushed under pressure through a 500 ⁇ m mesh while Sample B was pushed under pressure though a 300 ⁇ m mesh. The samples were used over a 3-month period and did not degrade during storage.
  • FIG. 1 shows a titration curve of the UV absorption values as a function of the concentration of glucuronolactone.
  • the supernatant liquids containing the uronic acid were then heated in a vigorously boiling bath of water for 30 minutes to denature the enzyme, and centrifuged again for 30 minutes to eliminate the enzyme. The volume of each tube was adjusted to 3.5 ml.
  • the concentration of UA released by hyaluronidase was determined from the titration curve shown in FIG. 1 by measuring UV absorption at 530 nm.
  • FIG. 2 shows a comparison of the different UV values.
  • the concentration of UA (in ⁇ g/ml of gel solution) after 5 days of incubation was determined from the titration curve ( FIG. 1 ).
  • a dilution factor of 7 i.e. 3.5/0.5 was taken into account as the 0.5 ml sample was diluted to a volume of 3.5 ml for analysis.
  • the tested gels were RestylaneTM gel at a concentration of 20 and 15 mg/ml, PerlaneTM gel at a concentration of 20 and 15 mg/ml and Sample A at a concentration of 20 and 15 mg/ml.
  • 0.25 ml of each gel was diluted in 2 ml of isopropanol. The residual gel, which was not destroyed by the enzyme, was precipitated and removed by centrifugation over 30 minutes.
  • Each tube of gel was then heated in a vigorously boiling bath of water for 30 minutes to denature the enzyme, and centrifuged again for 30 minutes to eliminate the enzyme. The volume of each tube was adjusted to 2 ml.
  • the concentration of UA released by hyaluronidase was determined from the titration curve by measuring UV absorption at 530 nm. The UV absorbance curve at day 1 for each gel is shown in FIG. 3 .
  • Sample A exhibited improved degradation (i.e. lower concentration of UA released), when compared to PerlaneTM and RestylaneTM gels. Indeed Sample A at a concentration of 20 mg/ml degraded less than PerlaneTM gel at a concentration of 15 mg/ml.
  • FIG. 5 shows the UV absorption at 530 nm after two days for each experiment.
  • Table 1 indicates that the degradation level generally increased with the decrease of the needle size. As shown in FIG. 6 , even when Sample A was extruded through a 32 G needle, the UA concentration remained below the values observed for both PerlaneTM gel and RestylaneTM gel without extrusion, thus indicating the improved degradation characteristics of Sample A.
  • results from Table 1 and Table 2 provided the basis to calculate the percentage of UA released in the experimental conditions listed below, relative to the maximum UA release that can be expected to measure for each gels:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
US10/552,881 2003-04-17 2004-04-16 Cross-linked polysaccharide composition Abandoned US20070026070A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/141,018 US8877243B2 (en) 2003-04-17 2013-12-26 Cross-linked polysaccharide composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003901834A AU2003901834A0 (en) 2003-04-17 2003-04-17 Cross-linked polysaccharide compositions
AU2003901834 2003-04-17
PCT/AU2004/000509 WO2004092223A1 (en) 2003-04-17 2004-04-16 Cross-linked polysaccharide composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2004/000509 A-371-Of-International WO2004092223A1 (en) 2003-04-17 2004-04-16 Cross-linked polysaccharide composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/141,018 Continuation US8877243B2 (en) 2003-04-17 2013-12-26 Cross-linked polysaccharide composition

Publications (1)

Publication Number Publication Date
US20070026070A1 true US20070026070A1 (en) 2007-02-01

Family

ID=31500871

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/552,881 Abandoned US20070026070A1 (en) 2003-04-17 2004-04-16 Cross-linked polysaccharide composition
US14/141,018 Expired - Fee Related US8877243B2 (en) 2003-04-17 2013-12-26 Cross-linked polysaccharide composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/141,018 Expired - Fee Related US8877243B2 (en) 2003-04-17 2013-12-26 Cross-linked polysaccharide composition

Country Status (13)

Country Link
US (2) US20070026070A1 (pt)
EP (1) EP1613663B1 (pt)
JP (2) JP2006523731A (pt)
KR (1) KR20060008906A (pt)
CN (1) CN100509858C (pt)
AT (1) ATE476450T1 (pt)
AU (1) AU2003901834A0 (pt)
BR (1) BRPI0409890A (pt)
CA (1) CA2522232C (pt)
DE (1) DE602004028455D1 (pt)
ES (1) ES2349924T3 (pt)
MX (1) MXPA05011098A (pt)
WO (1) WO2004092223A1 (pt)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281880A1 (en) * 2004-05-20 2005-12-22 Wei Wang Methods for making injectable polymer hydrogels
US20080050738A1 (en) * 2006-05-31 2008-02-28 Human Genetic Signatures Pty Ltd. Detection of target nucleic acid
US20080242738A1 (en) * 2005-09-27 2008-10-02 Universite Joseph Fourier-Grenoble 1 Hydrogel Functionalized with a Polymerizable Moiety and Their Uses as Biosensors or Bioreactors
US20080264590A1 (en) * 2002-09-13 2008-10-30 William Eamon Carrol Composition for increasing cellulosic product strength and method of increasing cellulosic product strength
US20080293637A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
US20090036403A1 (en) * 2007-07-30 2009-02-05 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20090042732A1 (en) * 2004-12-03 2009-02-12 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
US20090130657A1 (en) * 2004-09-10 2009-05-21 Human Genetic Signatures Pty Ltd. Amplification blocker comprising intercalating nucleic acids (ina) containing intercalating pseudonucleotides (ipn)
US20090143331A1 (en) * 2007-11-30 2009-06-04 Dimitrios Stroumpoulis Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090301712A1 (en) * 2008-03-27 2009-12-10 Greene, Tweed Of Delaware, Inc. Inert Substrate-Bonded Fluoroelastomer Components and Related Methods
WO2009154344A1 (ko) * 2008-06-18 2009-12-23 주식회사 바이오폴 조직 수복용 다공성 히알루론산-콜라겐 천연 고분자 지지체의 제조방법
US20100028437A1 (en) * 2008-08-04 2010-02-04 Lebreton Pierre F Hyaluronic Acid-Based Gels Including Lidocaine
US20100041013A1 (en) * 2005-09-14 2010-02-18 Human Genetic Signatures Pty Ltd. Assay for a health state
US20100092972A1 (en) * 2007-03-16 2010-04-15 Human Genetic Signatures Pty Ltd. Assay for gene expression
US20100098764A1 (en) * 2007-11-30 2010-04-22 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20100210587A1 (en) * 2007-09-28 2010-08-19 Shiseido Company Ltd. Swellable Crosslinked Hyaluronan Powder And Method For Producing The Same
EP2236523A1 (en) 2009-03-30 2010-10-06 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US7846693B2 (en) 2003-09-04 2010-12-07 Human Genetic Signatures Pty. Ltd. Nucleic acid detection assay
US20100316683A1 (en) * 2006-12-06 2010-12-16 Pierre Fabre Dermo-Cosmetique Hyaluronic acid gel for intradermal injection
US20110003700A1 (en) * 2007-12-20 2011-01-06 Human Genetic Signatures Pty Ltd. Elimination of contaminants associated with nucleic acid amplification
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US20110224164A1 (en) * 2010-03-12 2011-09-15 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US20110229574A1 (en) * 2010-03-22 2011-09-22 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20110263724A1 (en) * 2008-09-02 2011-10-27 Gurtner Geoffrey C Threads of hyaluronic acid and/or derivatives, thereof, methods of making thereof and uses thereof
US20110305744A1 (en) * 2010-06-09 2011-12-15 Farma-Derma Srl Preparation for vaginal and rectal use and relative production method
US20120071437A1 (en) * 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
US8338388B2 (en) 2003-04-10 2012-12-25 Allergan, Inc. Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8431347B2 (en) 2005-05-26 2013-04-30 Human Genetic Signatures Pty Ltd Isothermal strand displacement amplification using primers containing a non-regular base
WO2013164782A1 (en) 2012-05-03 2013-11-07 Medical And Biotechnological Services Srl In Abbreviated Form M.B.S. Srl Shape-memory cross-linked polysaccharides
US8685675B2 (en) 2007-11-27 2014-04-01 Human Genetic Signatures Pty. Ltd. Enzymes for amplification and copying bisulphite modified nucleic acids
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
EP2783702A4 (en) * 2011-11-24 2015-08-12 Amorepacific Corp Water-insoluble gel composition and process for its preparation
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US9371402B2 (en) 2009-04-09 2016-06-21 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9732375B2 (en) 2011-09-07 2017-08-15 Human Genetic Signatures Pty. Ltd. Molecular detection assay using direct treatment with a bisulphite reagent
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
CN113061265A (zh) * 2021-02-18 2021-07-02 中国人民解放军空军军医大学 一种多糖类水凝胶，其制备方法及其应用
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US11260015B2 (en) 2015-02-09 2022-03-01 Allergan Industrie, Sas Compositions and methods for improving skin appearance
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901834A0 (en) * 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
WO2008034176A1 (en) * 2006-09-19 2008-03-27 Ultraceuticals R & D Pty Ltd Cross-linked polysaccharide gels
JP2008255061A (ja) * 2007-04-06 2008-10-23 Shiseido Co Ltd 可溶性架橋ヒアルロン酸含有眼用組成物
WO2009043111A1 (en) * 2007-10-04 2009-04-09 Ultraceuticals R & D Pty Ltd Composition and method for dermal regeneration
CN101544705B (zh) * 2009-05-04 2011-09-14 西南大学 蔗糖缩水甘油醚交联剂、抗皱整理剂及其合成方法
BR112012000639B8 (pt) * 2009-07-10 2021-06-22 Medicaltree Patent Ltd dispositivo médico implantável para lubrificação de uma articulação sinovial
US11224516B2 (en) * 2009-07-10 2022-01-18 Peter Forsell Hip joint device and method
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
JP5684903B2 (ja) * 2010-06-08 2015-03-18 ダウ グローバル テクノロジーズ エルエルシー 粒状の可逆的に架橋したポリマー材料の調製方法
KR101240518B1 (ko) * 2012-03-26 2013-03-11 주식회사 제네웰 생체 적합성 고분자를 이용한 이식용 재료
KR101413510B1 (ko) * 2012-06-19 2014-07-02 주식회사 제네웰 생체 적합성 고분자를 이용한 이식용 재료의 제조방법
WO2014039012A1 (en) 2012-09-06 2014-03-13 Nanyang Technological University Hyaluronic acid-based drug delivery systems
FR3005056B1 (fr) * 2013-04-24 2016-04-01 Ayawane Hydrogel a base de polysaccharides natifs et/ou fonctionnalises, phosphates co-reticules
MX368941B (es) * 2013-06-28 2019-10-22 Galderma Sa Un procedimiento para preparar un producto de ácido hialurónico entrelazado.
EP3094672B1 (en) * 2014-01-17 2018-10-03 E. I. du Pont de Nemours and Company Production of a solution of cross-linked poly alpha-1,3-glucan and poly alpha-1,3-glucan film made therefrom
CN104387609B (zh) * 2014-11-18 2018-06-01 中国林业科学研究院林产化学工业研究所 一种纤维素多孔吸附材料的制备方法
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
CN104721873B (zh) * 2015-03-12 2016-06-29 北京蒙博润生物科技有限公司 片状交联透明质酸钠水凝胶的制备
AU2016352007B2 (en) 2015-11-12 2022-03-17 Terumo Kabushiki Kaisha Sustained-release topically administered agent
CN105504316B (zh) * 2016-01-29 2017-12-29 清华大学 一种透明质酸‑甲基纤维素复合凝胶的活性酯交联方法
CN107998437B (zh) * 2016-10-31 2021-07-13 常州药物研究所有限公司 纳米交联透明质酸钠凝胶及其制备方法和应用
KR20200007776A (ko) 2017-03-22 2020-01-22 제넨테크, 인크. 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
CN108047351A (zh) * 2017-12-15 2018-05-18 浙江景嘉医疗科技有限公司 一种低交联度透明质酸钠的制备方法
CN109531857B (zh) * 2019-01-02 2020-11-06 华熙生物科技股份有限公司 一种透明质酸或其盐颗粒的制备方法及所得产品
CN110038161B (zh) * 2019-04-29 2021-07-30 上海交通大学 一种新型透明质酸流动凝胶及其制备方法和应用
CN113413484B (zh) * 2021-06-21 2023-02-10 浙江苏嘉医疗器械股份有限公司 可用于人体软组织填充的植入材料
KR102640893B1 (ko) * 2021-11-12 2024-02-27 주식회사 유영제약 히알루론산 가교물을 포함하는 조성물의 제조방법
CN116207256A (zh) * 2022-09-23 2023-06-02 常熟威怡科技有限公司 一种电池的负极浆料及铜箔-石墨负极
CN117064067A (zh) * 2023-08-07 2023-11-17 湖北工业大学 一种具有可控酵解速率的膳食纤维及其制备方法与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4772419A (en) * 1985-03-01 1988-09-20 Pharmacia Ab Shaped article and processes for its preparation
US4963666A (en) * 1986-06-18 1990-10-16 Pharmacia Ab Material of polysaccharides containing carboxyl groups, and a process for producing such polysaccharides
US5411874A (en) * 1990-11-07 1995-05-02 Fermentech Medical Limited Production of hyaluronic acid
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5827937A (en) * 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US20030094719A1 (en) * 2001-05-02 2003-05-22 Jean-Dean Yang Method for producing water-insoluble polysaccharides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
CA1238043A (en) * 1983-12-15 1988-06-14 Endre A. Balazs Water insoluble preparations of hyaluronic acid and processes therefor
JPS60166301A (ja) * 1984-02-10 1985-08-29 Okura Ind Co Ltd セルロ−ス系材料成形品の製造方法
DE3726454A1 (de) * 1987-08-08 1989-02-16 Behringwerke Ag Thiolgruppenhaltige polymere, verfahren zu ihrer herstellung und ihre verwendung
JPH05140201A (ja) * 1991-11-25 1993-06-08 Shiseido Co Ltd 架橋ヒアルロン酸ゲル及びその製造方法
JPH06102229A (ja) * 1992-09-18 1994-04-15 Daikin Ind Ltd 半透性膜およびその製造方法
WO1994012105A1 (en) * 1992-12-02 1994-06-09 Shiseido Company, Ltd. Contact medium for probe of ultrasonic diagnostic apparatus
FR2717815A1 (fr) * 1994-03-25 1995-09-29 Gel Sciences Inc Nouveaux polymères gélifiables à base d'acide hyaluronique et leur procédé de préparation.
GB9902412D0 (en) * 1999-02-03 1999-03-24 Fermentech Med Ltd Process
NO314525B1 (no) * 1999-04-22 2003-03-31 Thin Film Electronics Asa Fremgangsmåte ved fremstillingen av organiske halvledende innretninger i tynnfilm
FR2811996B1 (fr) * 2000-07-19 2003-08-08 Corneal Ind Reticulation de polysaccharide(s), preparation d'hydrogel(s) ; polysaccharide(s) et hydrogel(s) obtenus,leurs utilisations
CA2351253A1 (en) * 2000-11-10 2002-05-10 Groupe Lysac Inc./Lysac Group Inc. Crosslinked polysaccharide, obtained by crosslinking with substituted polyethylene glycol, as superabsorbent
AU2003901834A0 (en) * 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4772419A (en) * 1985-03-01 1988-09-20 Pharmacia Ab Shaped article and processes for its preparation
US4963666A (en) * 1986-06-18 1990-10-16 Pharmacia Ab Material of polysaccharides containing carboxyl groups, and a process for producing such polysaccharides
US5676964A (en) * 1988-05-13 1997-10-14 Fidia, S.P.A. Crosslinked carboxy polysaccharides
US5411874A (en) * 1990-11-07 1995-05-02 Fermentech Medical Limited Production of hyaluronic acid
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses
US5827937A (en) * 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US20030094719A1 (en) * 2001-05-02 2003-05-22 Jean-Dean Yang Method for producing water-insoluble polysaccharides
US6852255B2 (en) * 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides

Cited By (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080264590A1 (en) * 2002-09-13 2008-10-30 William Eamon Carrol Composition for increasing cellulosic product strength and method of increasing cellulosic product strength
US10080767B2 (en) 2003-04-10 2018-09-25 Allergan Industrie Sas Injectable monophase hydrogels
US10653716B2 (en) 2003-04-10 2020-05-19 Allergan Industrie, Sas Injectable monophase hydrogels
US11045490B2 (en) 2003-04-10 2021-06-29 Allergan Industrie, Sas Injectable monophase hydrogels
US8338388B2 (en) 2003-04-10 2012-12-25 Allergan, Inc. Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US9062130B2 (en) 2003-04-10 2015-06-23 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US8563532B2 (en) 2003-04-10 2013-10-22 Allergan Industrie Sas Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained
US7846693B2 (en) 2003-09-04 2010-12-07 Human Genetic Signatures Pty. Ltd. Nucleic acid detection assay
US8168777B2 (en) 2004-04-29 2012-05-01 Human Genetic Signatures Pty. Ltd. Bisulphite reagent treatment of nucleic acid
US20050281880A1 (en) * 2004-05-20 2005-12-22 Wei Wang Methods for making injectable polymer hydrogels
US20090130657A1 (en) * 2004-09-10 2009-05-21 Human Genetic Signatures Pty Ltd. Amplification blocker comprising intercalating nucleic acids (ina) containing intercalating pseudonucleotides (ipn)
US7803580B2 (en) 2004-09-10 2010-09-28 Human Genetic Signatures Pty. Ltd. Amplification blocker comprising intercalating nucleic acids (INA) containing intercalating pseudonucleotides (IPN)
US8598088B2 (en) 2004-12-03 2013-12-03 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
US7833942B2 (en) 2004-12-03 2010-11-16 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
US20090042732A1 (en) * 2004-12-03 2009-02-12 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
US20110136098A1 (en) * 2004-12-03 2011-06-09 Human Genetic Signatures Pty. Ltd. Methods for simplifying microbial nucleic acids by chemical modification of cytosines
US8431347B2 (en) 2005-05-26 2013-04-30 Human Genetic Signatures Pty Ltd Isothermal strand displacement amplification using primers containing a non-regular base
US20100041013A1 (en) * 2005-09-14 2010-02-18 Human Genetic Signatures Pty Ltd. Assay for a health state
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
US7737240B2 (en) * 2005-09-27 2010-06-15 Universite Joseph Fourier-Grenoble 1 Hydrogel functionalized with a polymerizable moiety and their uses as biosensors or bioreactors
US20080242738A1 (en) * 2005-09-27 2008-10-02 Universite Joseph Fourier-Grenoble 1 Hydrogel Functionalized with a Polymerizable Moiety and Their Uses as Biosensors or Bioreactors
US20080050738A1 (en) * 2006-05-31 2008-02-28 Human Genetic Signatures Pty Ltd. Detection of target nucleic acid
US20100316683A1 (en) * 2006-12-06 2010-12-16 Pierre Fabre Dermo-Cosmetique Hyaluronic acid gel for intradermal injection
US20100092972A1 (en) * 2007-03-16 2010-04-15 Human Genetic Signatures Pty Ltd. Assay for gene expression
US20100099623A1 (en) * 2007-05-23 2010-04-22 Allergan, Inc. Cross-Linked Collagen and Uses Thereof
US20080293637A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20120071437A1 (en) * 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
US20090036403A1 (en) * 2007-07-30 2009-02-05 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8691957B2 (en) * 2007-09-28 2014-04-08 Shiseido Company, Ltd. Swellable crosslinked hyaluronan powder and method for producing the same
US20100210587A1 (en) * 2007-09-28 2010-08-19 Shiseido Company Ltd. Swellable Crosslinked Hyaluronan Powder And Method For Producing The Same
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8703118B2 (en) 2007-10-09 2014-04-22 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US8685675B2 (en) 2007-11-27 2014-04-01 Human Genetic Signatures Pty. Ltd. Enzymes for amplification and copying bisulphite modified nucleic acids
US20100098764A1 (en) * 2007-11-30 2010-04-22 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143331A1 (en) * 2007-11-30 2009-06-04 Dimitrios Stroumpoulis Polysaccharide gel formulation having increased longevity
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394783B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8513216B2 (en) 2007-11-30 2013-08-20 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20100004198A1 (en) * 2007-11-30 2010-01-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US20110003700A1 (en) * 2007-12-20 2011-01-06 Human Genetic Signatures Pty Ltd. Elimination of contaminants associated with nucleic acid amplification
US20090301712A1 (en) * 2008-03-27 2009-12-10 Greene, Tweed Of Delaware, Inc. Inert Substrate-Bonded Fluoroelastomer Components and Related Methods
WO2009154344A1 (ko) * 2008-06-18 2009-12-23 주식회사 바이오폴 조직 수복용 다공성 히알루론산-콜라겐 천연 고분자 지지체의 제조방법
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US8822676B2 (en) 2008-08-04 2014-09-02 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US10485896B2 (en) 2008-08-04 2019-11-26 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9089517B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11020512B2 (en) 2008-08-04 2021-06-01 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US20100028437A1 (en) * 2008-08-04 2010-02-04 Lebreton Pierre F Hyaluronic Acid-Based Gels Including Lidocaine
US9089518B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US8450475B2 (en) 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20110118206A1 (en) * 2008-08-04 2011-05-19 Allergan Industrie, Sas Hyaluronic acid based formulations
US10391202B2 (en) 2008-08-04 2019-08-27 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11173232B2 (en) 2008-08-04 2021-11-16 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9238013B2 (en) 2008-08-04 2016-01-19 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9358322B2 (en) 2008-08-04 2016-06-07 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11154484B2 (en) 2008-09-02 2021-10-26 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9228027B2 (en) * 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US20110263724A1 (en) * 2008-09-02 2011-10-27 Gurtner Geoffrey C Threads of hyaluronic acid and/or derivatives, thereof, methods of making thereof and uses thereof
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
EP2236523A1 (en) 2009-03-30 2010-10-06 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US9371402B2 (en) 2009-04-09 2016-06-21 Scivision Biotech Inc. Method for producing cross-linked hyaluronic acid
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US8946192B2 (en) 2010-01-13 2015-02-03 Allergan, Inc. Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9855367B2 (en) 2010-01-13 2018-01-02 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US10220113B2 (en) 2010-01-13 2019-03-05 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9655991B2 (en) 2010-01-13 2017-05-23 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US9333160B2 (en) 2010-01-13 2016-05-10 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10449268B2 (en) 2010-01-13 2019-10-22 Allergan Industrie, S.A.S. Stable hydrogel compositions including additives
US8921338B2 (en) 2010-03-12 2014-12-30 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US8586562B2 (en) 2010-03-12 2013-11-19 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US20110224164A1 (en) * 2010-03-12 2011-09-15 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US9125840B2 (en) 2010-03-12 2015-09-08 Allergan Industrie Sas Methods for improving skin conditions
US9585821B2 (en) 2010-03-12 2017-03-07 Allergan Industrie Sas Methods for making compositions for improving skin conditions
US10111984B2 (en) 2010-03-22 2018-10-30 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8691279B2 (en) 2010-03-22 2014-04-08 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9012517B2 (en) 2010-03-22 2015-04-21 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20110229574A1 (en) * 2010-03-22 2011-09-22 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US9480775B2 (en) 2010-03-22 2016-11-01 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20110305744A1 (en) * 2010-06-09 2011-12-15 Farma-Derma Srl Preparation for vaginal and rectal use and relative production method
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012054752A1 (en) * 2010-10-22 2012-04-26 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9962464B2 (en) 2011-06-03 2018-05-08 Allergan, Inc. Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US10994049B2 (en) 2011-06-03 2021-05-04 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
US9950092B2 (en) 2011-06-03 2018-04-24 Allergan, Inc. Dermal filler compositions for fine line treatment
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US10624988B2 (en) 2011-06-03 2020-04-21 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US11000626B2 (en) 2011-06-03 2021-05-11 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US9737633B2 (en) 2011-06-03 2017-08-22 Allergan, Inc. Dermal filler compositions including antioxidants
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US10434214B2 (en) 2011-09-06 2019-10-08 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9821086B2 (en) 2011-09-06 2017-11-21 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9795711B2 (en) 2011-09-06 2017-10-24 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11833269B2 (en) 2011-09-06 2023-12-05 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9732375B2 (en) 2011-09-07 2017-08-15 Human Genetic Signatures Pty. Ltd. Molecular detection assay using direct treatment with a bisulphite reagent
EP2783702A4 (en) * 2011-11-24 2015-08-12 Amorepacific Corp Water-insoluble gel composition and process for its preparation
WO2013164782A1 (en) 2012-05-03 2013-11-07 Medical And Biotechnological Services Srl In Abbreviated Form M.B.S. Srl Shape-memory cross-linked polysaccharides
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US11260015B2 (en) 2015-02-09 2022-03-01 Allergan Industrie, Sas Compositions and methods for improving skin appearance
US12011500B2 (en) 2015-02-09 2024-06-18 Allergan Industrie, Sas Compositions and methods for improving skin appearance
CN113061265A (zh) * 2021-02-18 2021-07-02 中国人民解放军空军军医大学 一种多糖类水凝胶，其制备方法及其应用

Also Published As

Publication number Publication date
ATE476450T1 (de) 2010-08-15
US8877243B2 (en) 2014-11-04
BRPI0409890A (pt) 2006-05-23
CA2522232C (en) 2007-07-03
WO2004092223A1 (en) 2004-10-28
ES2349924T3 (es) 2011-01-13
AU2003901834A0 (en) 2003-05-01
MXPA05011098A (es) 2005-12-15
EP1613663A4 (en) 2006-10-11
EP1613663B1 (en) 2010-08-04
DE602004028455D1 (de) 2010-09-16
CN1774450A (zh) 2006-05-17
KR20060008906A (ko) 2006-01-27
US20140105852A1 (en) 2014-04-17
JP2006523731A (ja) 2006-10-19
JP2008133474A (ja) 2008-06-12
EP1613663A1 (en) 2006-01-11
CN100509858C (zh) 2009-07-08
CA2522232A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US8877243B2 (en) Cross-linked polysaccharide composition
US20100035838A1 (en) Cross-linked polysaccharide gels
DK175661B1 (da) Polysaccharidestere
EP1753787B1 (en) Method of covalently linking hyaluronan and chitosan
KR920002702B1 (ko) 히알루론산의 가교결합형 에스테르와 그 염
RU2360928C2 (ru) Комплексная матрица для медико-биологического применения
EP1794192B1 (en) Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials made therefrom
EP1624935B1 (en) Anti-adhesion composites and methods os use thereof
US7521434B2 (en) Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them
US20080025950A1 (en) Modified Macromolescules and Associated Methods of Synthesis and Use
WO2008008859A2 (en) Macromolecules modified with electrophilic groups and methods of making and using thereof
US8530450B2 (en) Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics
CN101501075A (zh) 支化透明质酸和制造方法
CN114502599B (zh) 一种超支化聚甘油多缩水甘油醚及其作为多糖交联剂的用途
WO2012053776A2 (ko) 히알루론산계 화합물, 그 제조방법 및 용도
AU2004229592B2 (en) Cross-linked polysaccharide composition
US10857176B2 (en) Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan
US20110076243A1 (en) Modified hydrophilic polymers containing hydrophobic groups
EP4177276A1 (fr) Composition, sous forme de solution aqueuse comprenant au moins un compose macromoleculaire

Legal Events

Date Code Title Description
AS Assignment

Owner name: ULTRACEUTICALS R & D PTY. LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VONWILLER, SIMONE CHARLOTTE;HEBER, GEOFFREY KENNETH;REEL/FRAME:017945/0994

Effective date: 20060626

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE